Evaluation of the Final Adult Height and Its Determinants in Patients with Growth Hormone Deficiency: A Single-centre Experience from the South-Eastern Region of Turkey
Open Access
- 1 September 2020
- journal article
- research article
- Published by Galenos Yayinevi in Journal of Clinical Research in Pediatric Endocrinology
- Vol. 12 (3), 295-302
- https://doi.org/10.4274/jcrpe.galenos.2020.2019.0218
Abstract
Objective: The aim was to determine the final adult height (FAH) achieved by recombinant human growth hormone (rhGH) treatment, the factors affecting (FAH) and the success of attaining the genetic potential. Methods: Data of 133 patients treated with rhGH therapy were reviewed retrospectively. Patients were grouped according to diagnosis, either isolated GH deficiency (IGHD) or multiple pituitary hormone deficiency (MPHD), and by sex, and pubertal status at the beginning of treatment. Results: The mean age of initiation of treatment was 12.3 +/- 2.18 years, and the mean duration of rhGH treatment was 3.65 +/- 1.5 years. The mean height standard deviation score (SDS) at diagnosis was -3.11 +/- 0.75 SD. All patients received a standardized GH dose of 0.033 mg/kg/day. Mean FAH-SDS was -1.8 +/- 0.77 and delta height-SDS (the change in height SDS between the beginning and end of treatment) was 1.28 +/- 0.94 SD. FAH-SDS was -1.79 +/- 0.86 SD in males; -1.82 +/- 0.64 in females (p =0.857); -1.94 +/- 0.71 at the beginning of treatment in pubertal patients and -1.68 +/- 0.81 in prepubertal patients (p = 0.056); -1.84 +/- 0.89 in patients with IGHD and -0.47 +/- 0.2 in patients with MPHD (p>0.05). In multiple regression analysis, First year delta height-SDS was the most predictive factor for both FAH-SDS and delta height-SDS. Conclusion: The majority of our patients achieved a final height compatible with their genetic potential as well as population standards when treated with rhGH even having started at a relatively late age. First year delta height-SDS was a predictive factor for FAH.Keywords
This publication has 25 references indexed in Scilit:
- Growth Hormone Dose-Dependent Pubertal Growth: A Randomized Trial in Short Children with Low Growth Hormone SecretionHormone Research in Paediatrics, 2014
- The Challenge of Growth Hormone Deficiency Diagnosis and Treatment during the Transition from Puberty into AdulthoodFrontiers in Endocrinology, 2013
- Response to Growth Hormone Treatment in Isolated Growth Hormone Deficiency versus Multiple Pituitary Hormone DeficiencyHormone Research in Paediatrics, 2011
- A Randomised Study of Two Doses of Biosynthetic Human Growth Hormone on Final Height of Pubertal Children with Growth Hormone DeficiencyHormone Research in Paediatrics, 2008
- Final Height in Children with Idiopathic Growth Hormone Deficiency Treated with a Fixed Dose of Recombinant Growth HormoneHormone Research in Paediatrics, 2007
- Prediction of Adult Height in Growth-Hormone-Treated Children with Growth Hormone DeficiencyJournal of Clinical Endocrinology & Metabolism, 2007
- Adult Height in Patients with Permanent Growth Hormone Deficiency with and without Multiple Pituitary Hormone DeficienciesJournal of Clinical Endocrinology & Metabolism, 2006
- Effect of Growth Hormone (GH) Treatment on the Near-Final Height of 1258 Patients with Idiopathic GH Deficiency: Analysis of a Large International DatabaseJournal of Clinical Endocrinology & Metabolism, 2006
- High Dose Recombinant Human Growth Hormone (GH) Treatment of GH-Deficient Patients in Puberty Increases Near-Final Height: A Randomized, Multicenter Trial1Journal of Clinical Endocrinology & Metabolism, 2000
- Towards a Consensus on the Definition of Idiopathic Short StatureHormone Research, 1996